Companies featured in this edition of the newsletter: ACTC, CUR, CVM, DKAM, ENZ, IMUC, MFGD, NXOI, OMCM, ONEZ, PSID, XSNX

Markets continued to carry momentum during the early stages of last week, as the absence of significant economic news led to a continuation of the upward trend characterizing the past few weeks, until an earnings miss from Dell on Thursday led to a selloff in the technology sector which caused the major indices to end the week mixed. All told, the Dow ended the week in positive territory, gaining 47 points to close at 10318, up 0.5% on the week and 17.6% on the year. The Nasdaq surrendered 1.0% to close at 2146, paring its YTD gains to 36.1%, while the S&P 500 and Russell 2000 lost 0.2% and 0.3% respectively, reducing their yearly gains to 20.8 and 17.1.

Things got off to a strong start on Monday, with the

...

Today, International Stem Cell Corporation announced that it will collaborate with renowned stem cell researcher Jeanne F. Loring, Ph.D. and the Scripps Research Institute (located in La Jolla, CA) to study parthenogenetic stem cells and their potentially derived therapeutic cells. The study expands the company’s mission to generate data necessary to understand these cells and move them closer to the clinic.

ISCO has perfected a process using unfertilized human eggs to creating human stem cells. These “parthenogenetic” stem cells allow immune-matching to large segments of the population. ISCO’s process allows the company to avoid the ethical debate regarding the use of human embryos.

Company scientists have derived a type of cell found in the human eye from parthenogenetic stem cells that may have application in the treatment of macular degeneration, a common eye disease. Dr. Loring and ISCO will study these cells as part of the collaboration.

According to

...

Alcon, Inc. (ACL) recently entered into an in-licensing agreement with Potentia Pharmaceuticals, a privately-held biotechnology company that focuses on the development of medicines for the treatment of age-related macular degeneration (AMD). Alcon gained the right to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. Alcon also gained the right to acquire Potentia’s shares on the achievement of certain development milestones and if Alcon opts to continue with the development of POT-4.   Alcon will make upfront payments to Potentia for the initial license and option rights. Potentia is also entitled to receive future payments based on the achievement of several clinical and global regulatory approval milestones for different therapeutic indications and on Alcon's decision to proceed with development. Potentia will also receive royalties based on sales of any products that are approved and commercialized under this agreement.   POT-4 is a complement inhibitor, which is ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMLN, PWRM, MMM, CSRH, MYL, CVAT, STEM, AQNM

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

AMLN will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a

...

On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets.    Under the terms of the agreement, SurModics is entitled to an up-front payment of $3.5 million. Furthermore, the deal could be worth up to $200 million in delayed payments if multiple products are successfully developed. SurModics will also receive royalties on product sales. SurModics will receive payments for its development services. Under the terms of the agreement, Roche and Genentech have the right to obtain manufacturing services from SurModics.   The transaction provides Roche and Genentech complete access to the biodegradable microparticles developed by SurModics. They intend to use the products in a long-lasting version of their optical drug Lucentis ...

On early Tuesday morning, SurModics announced their new licensing deal with Roche. SurModics Inc. said that they have licensed their drug delivery technology to Roche and Roche’s Genentech unit for a deal that could be worth around US$ 200 million. The news about the new licensing deal by SurModics gave a great boost to the shares of SurModics and they started climbing in the morning trading itself.  The shares were around $5.97, or 24.6 percent, to $30.24 in the morning trade, but it quickly moved up and halted at $29.04. SurModics shares have normally traded between $15.96 to $30.75 in the previous years.

Roche is based in Switzerland and is one of the world’s biggest drugmakers. However, it has been acquired by a San Francisco biotechnology company called Genentech in 2008.

...

SurModics, Inc. announced yesterday that it has signed an exclusive agreement with the Roche Group and Genentech for the licensing of its proprietary drug delivery system. This agreement will also establish a development process whereby a new, sustained-delivery formulation for the highly successful Lucentis® (ranibizumab) injection will be commercialized and brought to market using SurModics’ technology, logistics and expertise.

This incredibly lucrative agreement includes an initial, up-front licensing fee of $3.5 million, and an estimated $200 million in payments if development of the Lucentis formulation and other products is successful. In addition, the agreement indicates that SurModics will be used to develop and manufacture the drug. With the potential to develop other drugs in the future via this agreement, SurModics will also obtain certain undisclosed royalties on sales of developed products.

Lucentis is the only FDA-approved treatment for neovascular (wet) age-related macular degeneration (ARMD), a degenerative condition of the central retina,

...

Last week, Regeneron Pharmaceuticals, Inc. (REGN) announced the completion of enrollment in two late stage studies of its VEGF (vascular endothelial growth factor) trap-eye treatment for age-related macular degeneration (wet AMD), a leading cause of blindness in adults. Each of the randomized, double-masked trials has enrolled more than the target of 1,200 patients. The company is developing the drug in partnership with Bayer HealthCare (BAYRY.PK). The study will be a non-inferiority comparison of the VEGF trap-eye with ranibizumab (Lucentis from Genentech, Inc- now a wholly owned subsidiary of the Roche group (RHHBY.PK)), an anti-angiogenic agent approved for use in wet AMD. The company expects one-year primary endpoint data from both studies in the fourth quarter of 2010. As a reminder, Regeneron and Bayer HealthCare entered into a collaboration agreement in Oct 2006 for the development and commercialization of the VEGF trap-Eye outside ...

For Immediate Release

Chicago, IL – September 18, 2009 – Zacks Equity Research highlights ON Semiconductor (ONNN) as the Bull of the Day and Developers Diversified (DDR) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Alcon Inc.(ACL), AstraZeneca (AZN) and Allergan, Inc.(AGN).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

ON Semiconductor (ONNN) is an OEM of primarily analog semiconductors used within a diverse set of end markets. June quarter results beat consensus expectations, with management guiding for stronger results in the September quarter.

Recent acquisitions, a broad product portfolio, a well diversified business across end markets and geographies, restructuring actions and debt reduction initiatives are other positive factors.

While competition is strong as ever and restrictive covenants and some residual integration

...

Adeona Pharmaceuticals, Inc.

(Public, AMEX:AEN)

StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, Oral dnaJP1 which is an immunotherapy for rheumatoid arthritis (RA) patients. If these products aren’t enough to entice your way into purchasing this stock, take a look at the recent $5 million dollar cash infusion from the National Multiple Sclerosis Society (NMSS), billions of dollars in product market potential, purchasing of Hartlab LLC, an independent Chicago-area CLIA-certified clinical reference laboratory, an experienced management team that will have you feeling like a kid in a candy store, and to

...